Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 18/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | NQO1 | P15559 | 4/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220854 | 0.89 | NQO2 (0.71) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13916795 | 0.89 | NQO2 (0.68) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL753153 | 0.87 | NQO2 (0.66) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13916807 | 0.84 | NQO2 (0.64) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL6503570 | 0.81 | NQO2 (0.58) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13928512 | 0.79 | NQO2 (0.76) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL6502756 | 0.78 | NQO2 (0.56) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7062442 | 0.76 | NQO2 (0.52) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526727 | 0.75 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7059459 | 0.75 | NQO2 (0.65) | NQO2SMARCA2NSD2NQO1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326950-B2 | Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-05-03 | — | — | US | disclosed |
| US-20130316957-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2013-11-28 | — | — | US | disclosed |
| US-8546524-B2 | Smoothened polypeptides and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120282196-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-11-08 | — | — | US | disclosed |
| US-8198402-B2 | Smoothened polypeptides and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-12 | — | — | US | disclosed |
| EP-2431388-A1 | Smoothened polypeptides and methods of use | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100093625-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100034896-A1 | SELF-ASSEMBLING NANOPARTICLES COMPOSED OF TRANSMEMBRANE PEPTIDES AND THEIR APPLICATION FOR SPECIFIC INTRA-TUMOR DELIVERY OF ANTI-CANCER DRUGS | The United States of America,as represented by the Se ecting the Add button. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093625-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | NQO2 4582/4885SMARCA2 2287/4885NSD2 2619/4885 |
| US-20130316957-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | NQO2 4582/4885SMARCA2 2287/4885NSD2 2619/4885 |
| US-20120282196-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | NQO2 4582/4885SMARCA2 2287/4885NSD2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.